Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review

Date: August 9, 2016
Pages: 64
Price:
US$ 125.00
License [?]:
Publisher: GlobalData
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: EA84063DD6AEN
Leaflet:

Download PDF Leaflet

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review
Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Eisai Co., Ltd. (Eisai) is one of the leading pharmaceutical companies in Japan. It undertakes the research, development, manufacture and marketing of pharmaceuticals, including over-the-counter (OTC) drugs and pharmaceutical production systems, besides chemicals, food ingredients and additives, dietary supplements and cosmetics. The company’s franchise areas in research include neurology, oncology, vascular and immunological reaction, gastrointestinal disorders, and musculoskeletal diseases. Eisai’s major products include proton pump inhibitor; Aricept, an anti-Alzheimer's agent; Halaven, a novel anti-cancer agent; Fycompa, an anti-epileptic and peripheral neuropathy treatment, among others. Eisai has ten major subsidiaries, two production plants, a research lab and an industrial complex. Outside Japan, the company operates in North America, Europe and Asia. Eisai is headquartered in Tokyo, Japan.

Eisai Co., Ltd. Key Recent Developments

Jul 11, 2016: NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care
Jun 30, 2016: Eisai Listed For 15th Consecutive Year In FTSE4Good Index Series, An Index For Socially Responsible Investment
Apr 06, 2016: Eisai and PharmStandard Sign Cooperation Agreements in Russia
Feb 15, 2016: Eisai and Charles River Laboratories Announce Collaboration for New Drug Discovery
Oct 12, 2015: Dementia Consortium signs new pharma partner Astex Pharmaceuticals

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company. - The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably. - Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance. - Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research. - Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.Note: Some sections may be missing if data is unavailable for the company
SECTION 1 - ABOUT THE COMPANY

Eisai Co., Ltd. - Key Facts
Eisai Co., Ltd. - Key Employees
Eisai Co., Ltd. - Key Employee Biographies
Eisai Co., Ltd. - Key Operational Employees
Eisai Co., Ltd. - Major Products and Services
Eisai Co., Ltd. - Pharmaceutical Pipeline Products Data
Eisai Co., Ltd., Pipeline Products by Therapy Area
Eisai Co., Ltd., Pipeline Products by Development Phase
Eisai Co., Ltd. - History
Eisai Co., Ltd. - Company Statement
Eisai Co., Ltd. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Eisai Co., Ltd. - Business Description
Eisai Co., Ltd. - Corporate Strategy
Eisai Co., Ltd. - SWOT Analysis
SWOT Analysis - Overview
Eisai Co., Ltd. - Strengths
Strength - Unique Products
Strength - Strong R&D Activities
Strength - Production Facilities
Eisai Co., Ltd. - Weaknesses
Weakness - Loss of Exclusivity: Pariet/ AcipHex
Weakness - Revenue Decline in Japan
Weakness - Discontinuation of Product Development
Eisai Co., Ltd. - Opportunities
Opportunity - Product Approvals and Launches
Opportunity - Strategic Agreements
Opportunity - Business Initiatives
Eisai Co., Ltd. - Threats
Threat - Influx of Generics
Threat - Expansion by Competitors
Threat - Stringent regulations
Eisai Co., Ltd. - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eisai Co., Ltd., Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 11, 2016: NTT IT, NTT East and Eisai Rollout Interprofessional Collaboration Business for Medical Treatment and Care
Jun 30, 2016: Eisai Listed For 15th Consecutive Year In FTSE4Good Index Series, An Index For Socially Responsible Investment
Apr 06, 2016: Eisai and PharmStandard Sign Cooperation Agreements in Russia
Feb 15, 2016: Eisai and Charles River Laboratories Announce Collaboration for New Drug Discovery
Oct 12, 2015: Dementia Consortium signs new pharma partner Astex Pharmaceuticals
Jul 16, 2015: Eisai Enters Agreement To Transfer North Carolina Plant In The U.S. To Biogen
May 21, 2015: Eisai To Promote Clinical Trial Data Disclosure For The Advancement Of Science And Medicine
Apr 13, 2015: Eisai and Genomics to Collaborate in Analyses of Large-Scale Genotype/Phenotype Data to Inform Drug Development
Apr 03, 2015: Niigata University And Eisai Present Results Of Joint Research In U.S. Academic Journal
Mar 04, 2015: Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

LIST OF TABLES

Eisai Co., Ltd., Key Facts
Eisai Co., Ltd., Key Employees
Eisai Co., Ltd., Key Employee Biographies
Eisai Co., Ltd., Key Operational Employees
Eisai Co., Ltd., Major Products and Services
Eisai Co., Ltd., Number of Pipeline Products by Therapy Area
Eisai Co., Ltd., Number of Pipeline Products by Development Stage
Eisai Co., Ltd., Pipeline Products By Therapy Area and Development Phase
Eisai Co., Ltd., History
Eisai Co., Ltd., Subsidiaries
Eisai Co., Ltd., Joint Venture
Eisai Co., Ltd., Key Competitors
Eisai Co., Ltd., Ratios based on current share price
Eisai Co., Ltd., Annual Ratios
Eisai Co., Ltd., Interim Ratios
Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals By Type, 2010 to YTD 2016
Eisai Co., Ltd., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

LIST OF FIGURES

Eisai Co., Ltd., Pipeline Products by Therapy Area
Eisai Co., Ltd., Pipeline Products by Development Phase
Eisai Co., Ltd., Performance Chart (2012 - 2016)
Eisai Co., Ltd., Ratio Charts
Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016
Eisai Co., Ltd., Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016
Skip to top


Ask Your Question

Eisai Co., Ltd. (4523) - Financial and Strategic SWOT Analysis Review
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: